From the Guidelines
Alogliptin doses for type 2 diabetes mellitus are 25 mg daily if eGFR > 60 mL/min/1.73 m², 12.5 mg daily if eGFR 30 to 60 mL/min/1.73 m², and 6.25 mg daily if eGFR < 30 mL/min/1.73 m².
Dosing Considerations
- The dosing of alogliptin is based on the patient's estimated glomerular filtration rate (eGFR) due to its renal excretion 1.
- For patients with an eGFR > 60 mL/min/1.73 m², the recommended dose is 25 mg daily.
- For patients with an eGFR between 30 to 60 mL/min/1.73 m², the recommended dose is 12.5 mg daily.
- For patients with an eGFR < 30 mL/min/1.73 m², the recommended dose is 6.25 mg daily.
Additional Information
- Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones to enhance glucose-dependent insulin secretion 2, 3.
- The maximum approved daily dose of alogliptin is 25 mg 2, 3.
- It's essential to consider the patient's renal function when prescribing alogliptin, as dose adjustments are necessary to minimize the risk of adverse effects 1.
From the FDA Drug Label
The peak inhibition of DPP-4 exceeded 93% across doses of 12. 5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Multiple-dose administration of alogliptin to patients with type 2 diabetes also resulted in a peak inhibition of DPP-4 within one to two hours and exceeded 93% across all doses (25 mg, 100 mg and 400 mg) after a single dose and after 14 days of once-daily dosing. At the maximum recommended clinical dose of 25 mg, alogliptin tablets were eliminated with a mean terminal half-life (T1/2) of approximately 21 hours.
The doses of alogliptin (Nesina) for type 2 diabetes mellitus are:
- 25 mg: the maximum recommended clinical dose
- 12.5 mg to 800 mg: doses that exceeded 93% peak inhibition of DPP-4
- 25 mg, 100 mg, and 400 mg: doses used in multiple-dose administration to patients with type 2 diabetes 4
From the Research
Alogliptin Dosing for Type 2 Diabetes Mellitus
- The recommended dose of alogliptin for type 2 diabetes mellitus is not explicitly stated in the provided studies, but it is mentioned that alogliptin is administered once daily 5, 6.
- Alogliptin can be used as monotherapy or in combination with other antidiabetic agents, such as metformin and pioglitazone 5, 7, 8.
- The studies suggest that alogliptin is effective and well-tolerated in patients with type 2 diabetes mellitus, with a low risk of hypoglycemia and weight gain 7, 9, 8.
- Alogliptin has been shown to improve glycemic control when administered as monotherapy or in combination with other antidiabetic agents 5, 7, 8.
Available Formulations
- Alogliptin is available as a single-agent formulation (Nesina, Vipidia) 8.
- Fixed-dose combinations of alogliptin with metformin (Kazano, Vipdomet) and alogliptin with pioglitazone (Oseni, Incresync) are also available 5, 8.
Clinical Efficacy and Tolerability
- Alogliptin has been shown to be effective in improving glycemic control in patients with type 2 diabetes mellitus, with a favorable safety profile 7, 9, 8.
- The results of clinical trials have demonstrated that alogliptin is well-tolerated, with a low risk of adverse events such as hypoglycemia, weight gain, and gastrointestinal distress 7, 9, 8.